which reinforces the need to firm bright light therapy as an efficient adjunctive treatment for non-seasonal depressive ...

Shares of Cybin, Inc. ($CYBN) surged as much as 10% on Monday, reaching their highest level since May, following the ...

The global major depressive disorder (MDD) treatment market is expected to experience steady growth, projected to develop at ...

Psilocybin-assisted therapy could potentially benefit up to 5.6 million Americans with major depressive disorder or treatment ...

Acupuncture. Ketamine infusions. "Electroshock" or electroconvulsive therapy. The existing treatment options for those ...

Patients with non-seasonal depression who were treated with bright light therapy reported a 40% remission rate, according to a recent study.

Bright light therapy, a standard treatment for seasonal depression, may also help people who experience depression year-round ...

(SILO), Monday announced positive results from a pre-clinical study of SPC-15 showing potential for the treatment of major depressive disorder, and other severe stress-related conditions ... severe ...

TORONTO--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough ...

“Economic Burden of Treatment-Resistant Depression among Adults with Chronic Non-Cancer Pain Conditions and Major Depressive Disorder in the US.” GoodTherapy: “How Much Does Therapy Cost?

Repetitive transcranial magnetic stimulation offers rapid depression relief for patients unresponsive to conventional ...

The Horizon 3.0 TMS Therapy System is a computerized, noninvasive medical device that directs electrical currents at different regions of the cerebral cortex.